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Abstract
Purpose—Typically, low molecular weight cationic peptides or polymers exhibit poor
transfection efficiency due to an inability to condense plasmid DNA into small nanoparticles.
Here, efficient gene delivery was attained using TAT/pDNA complexes containing calcium
crosslinks.
Methods—Electrostatic complexes of pDNA with TAT or PEI were studied with increasing
calcium concentration. Gel electrophoresis was used to determine DNA condensation. The
morphology of the complexes was probed by transmission electron microscopy. Transfection
efficiency was assessed using a luciferase reporter plasmid. The accessibility of phosphate and
amine groups within complexes was evaluated to determine the effect of calcium on structure.
Results—TAT/pDNA complexes were condensed into small, 50–100 nm particles by optimizing
the concentration of calcium. Complexes optimized for small size also exhibited higher
transfection efficiency than PEI polyplexes in A549 cells. TAT and TAT complexes displayed
negligible cytotoxicity up to 5 mg/mL, while PEI exhibited high cytotoxicity, as expected. Probing
the TAT-Ca/pDNA structure suggested that calcium interacted with both phosphate and amine
groups to compact the complexes; however, these “soft” crosslinks could be competitively
disrupted to facilitate DNA release.
Conclusion—Small and stable TAT-Ca/pDNA complexes were obtained via “soft” calcium
crosslinks leading to sustained gene expression levels higher than observed for control PEI gene
vectors. TAT-Ca/pDNA complexes were stable, maintaining particle size and transfection
efficiency even in the presence of 10% of FBS. TAT-Ca complexes offer an effective vehicle
offering potential for translatable gene delivery.
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INTRODUCTION
Intensive effort has been devoted to develop gene therapy systems capable of overcoming a
variety of limitations, including low gene transfection efficiency, toxicity, and in vivo
instability (1–7). Nonviral vectors have been given considerable attention as gene delivery
vehicles because of their presumed safety, ease of synthesis, relatively unrestricted vector
size, low cost, and low degree of immunogenicity in comparison to viral vectors (8).
Plasmid DNA complexed with cationic lipids (lipoplexes) and polymers (polyplexes) are the
most commonly employed nonviral gene delivery vehicles (9–17). Because naked plasmid
DNA does not easily penetrate cellular membranes (18), nonviral gene delivery systems may
include agents to improve intracellular delivery in an effort to promote transfection. Finally,
gene delivery vehicles are subject to dilution, degradation and elimination in vivo, which
amplify the need for safe and efficient gene delivery at high doses of DNA.
New strategies have been put forward to enhance cellular uptake of gene delivery vehicles,
among which peptides enhancing cell adhesion and internalization have reached a prominent
position (19). Peptide sequences, also designated as protein transduction domains (PTD) or
membrane translocalization signals (MTS), were identified as potentially useful labels for
intracellular delivery of peptides, proteins, oligonucleotides, and plasmid DNA (20–24). By
modifying the surface of gene delivery vectors with cell-penetrating peptides (CPPs),
vectors have been shown to traverse the membranes of biological cells within seconds to
minutes (25). Polycationic CPPs have even been reported to enhance cell permeability and
facilitate the intracellular delivery of nanoparticles (26).
The mechanism of cell entry of CPPs alone or with their cargoes still remains somewhat of
an enigma. Some reports indicating that cellular translocation of CPPs is energy as well as
endocytosis independent and that there is direct transfer of the peptides through the lipid
bilayer by inverted micelle formation (27–32). Another report, however, proposed an energy
dependent mechanism of cell entry of CPPs (33), which may also involve extracellular
heparan sulfate and various endocytosis and macropinocytosis pathways (34–41). It was also
suggested that classical and nonclassical endocytosis pathways may be associated
simultaneously with CPP translocation, depending upon the biophysical properties of CPPs
and their cargo (32,42,43).
One particular CPP of interest is the HIV-1 TAT peptide. This peptide, which represents a
protein transduction domain (44,45) and a nuclear localization sequence (NLS) (46), has
been reported to show unusual translocation abilities by directly crossing biological
membranes independent of receptors and temperature (47). In addition, the NLS function of
TAT peptide could facilitate nuclear localization of a therapeutic agent due to interaction
with the endogenous cytoplasmic nuclear transport machinery. The cationic nature of the
TAT sequence arising from several arginine residues has already been utilized in gene
delivery either by covalent coupling of this CPP to the gene delivery vehicle (48–50) or by
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simple mixing of plasmid DNA with TAT to form TAT/pDNA complexes via noncovalent
electrostatic interactions (51–54). However, the transfection efficiency of such complexes
remains quite low and requires improvement.
Obviously, a strong affinity between TAT peptide and plasmid DNA is required to stabilize
the resulting polyplex and to achieve an optimized transfection yield. On the other hand, a
sufficiently low affinity between TAT peptide and plasmid DNA is desired to facilitate the
release of the cargo after cellular uptake. Thus, the critical balance between the TAT/pDNA
binding affinities has important consequences for enhancing the transfection efficiency. Our
objective was to design a more efficient and less toxic means of gene delivery using TAT/
pDNA complexes containing “soft” crosslinks. Calcium was found to control the delicate
balance between binding affinities within TAT/pDNA polyplexes. The addition of CaCl2 to
TAT/pDNA complexes directly affected particle size and transfection efficiency in a
concentration-dependent manner. The optimum calcium concentration (0.3 M) resulted in a
1,000-fold enhancement in TAT/pDNA polyplex transfection efficiency and showed no
detectable cytotoxicity. Gene transfection levels were as high as that observed for PEI
polyplexes, suggesting the possible translation of the TAT-Ca/pDNA complexes.
MATERIALS AND METHODS
Materials
Plasmid DNA encoding firefly luciferase (pGL3, 4.8 kbp) was obtained from Promega
(Madison, WI, USA) and transformed into Escherichia coli DH5ά (Invitrogen, Carlsbad,
CA). A single transformed colony picked from an agar plate was cultured in LB Broth Base
(Invitrogen) liquid for plasmid DNA preparation. Plasmid DNA was purified with Plasmid
Giga Kit 5 (Qiagen, Germantown, MD) following the manufacturer’s instructions. All
pDNA had purity levels of 1.8 or greater as determined by UV/Vis inspection (A260/A280).
TAT peptide (RKKRRQRRR; Mw=1338.85 Da, TFA salt=2632.9 Da) was synthesized in
house. Branched polyethylenimine (PEI, 25 kDa) was obtained from Aldrich (Milwaukee,
WI). Calcium chloride (CaCl2. 2H2O) and agarose medium were purchased from Fisher
Scientific (Pittsburgh, PA). A549 cells were obtained from the American Type Culture
Collection (ATCC, Rockville, MD). The cell culture medium (Ham’s F-12 Nutrient
Mixture, Kaighn’s modified with L-glutamine) was purchased through Fisher Scientic. Fetal
bovine serum (FBS) was purchased from Hyclone. Penicillin-streptomycin was purchased
from MB Biomedical, LLC. Trypsin-EDTA was purchased through Gibco. MTS reagent
[tetrazolium compound; 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt] was purchased from Promega. Heparin Sodium was
obtained from Spectrum (Gardena, CA).
Preparation of TAT-Ca/pDNA Complexes
TAT/pDNA complexes were synthesized by rapidly adding 10µL (0.1µg/µL) of pDNA to
15µL (N/P ratio of 25) TAT solution while pipetting. To this solution, 15µL of known
molarity (e.g. 0.3 M) CaCl2 was added and mixed by vigorous pipetting followed by 15–20
min incubation at 4°C prior to use.
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Formation of PEI/pDNA Complexes
PEI-DNA complexes were prepared by adding 10µl (0.1 µg/µL) of pDNA solution to 15µL
(N/P ratio of 5 or 10) PEI solution dropwise while stirring. Complexes were incubated at
room temperature for 20–30 min before dilution 1.7 times (15µL) with the appropriate
buffer (e.g. nuclease-free water or CaCl2 solution). Complexes were freshly prepared before
each individual experiment.
Size and Zeta Potential Measurement
Suspensions containing complexes with TAT or PEI were prepared as described earlier
using a DNA concentration of 0.1µg/µL. All samples intended for light scattering analyses
were prepared using 10 mM Tris buffer, pH 7.4, which was prefiltered with a 0.22µm filter
to remove any trace particulates. Particle sizes were measured by dynamic light scattering
(DLS) using a Brookhaven (Holtsville, NY) instrument equipped with a 9000AT
autocorrelator, a 50 mW HeNe laser operating at 532 nm (JDS Uniphase), an EMI 9863
photomultiplier tube, and a BI 200 M goniometer. The light scattered at 90° from the
incident light was fit to an autocorrelation function using the method of cumulants. Zeta
potential measurements were obtained by phase analysis light scattering using a Brookhaven
Zeta PALS instrument. The electrophoretic mobility of the samples was determined from the
average of 10 cycles of an applied electric field. The zeta potential was determined from the
electrophoretic mobility from the Smoluchowski approximation. Zeta potential was
determined in 1 mM KCl solution.
Agarose Gel Electrophoresis Assays
The pDNA binding ability of the TAT, TAT-Ca, CaCl2 and PEI complexes was analyzed by
agarose gel electrophoresis. The TAT-Ca/pDNA and PEI/DNA complexes containing 1µg
luciferase reporter gene were prepared as described at various N/P ratios. The N/P ratio
refers to the molar ratio of amine groups in the cationic polymer, which represent the
positive charges, to phosphate groups in the plasmid DNA, which represent the negative
charges. The DNA complex suspensions (i.e. 25µL) at various N/P ratios were diluted by
adding 4µL of 10× Tris-acetate-EDTA (TAE) gel running buffer (Promega) and 4µL of
100× SYBR Green (Invitrogen) solutions. The DNA loading buffer (7µL of 6×) was added
to the complex suspensions. The mixtures were allowed to incubate at room temperature for
40 min to ensure labeling of the DNA with the SYBR Green dye. Thereafter, the complexes
were loaded into individual wells of 1% agarose/ 1× TAE gel buffer, and subjected to
electrophoresis at 110 V for 30 min. Uncomplexed DNA diluted with an identical volume of
solution was used as a control. The resulting DNA migration patterns were revealed using an
AlphaImager® Imaging System (Alpha Innotech, San Leandro, CA).
Cell Culture
Culturing of human epithelial lung cell line A549 was performed according to the protocol
provided by the American Type Culture Collection. A549 cells were grown in F-12K
supplemented with 10% v/v FBS and 1% v/v Penicillin/streptomycin at 37° C in a
humidified air atmosphere containing 5% CO2.
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In Vitro Cell Transfection Studies
A549 cells were trypsinized, counted and diluted to a concentration of approximately 80,000
cells/ mL. Then 0.1 mL of that dilution was added to each well of a 96-well plate, and the
cells were incubated in a humidified atmosphere at 5%CO2 and 37°C for 24 h. Immediately
before transfection, the cells were washed once with PBS and 100µl sample (20% of
complex to 80%of serum-free cell culture medium) was added to each well. Cells were
incubated with the complexes for 5 h. The transfection agent was then removed by
aspiration, and 100µL of fresh serum medium was added followed by further incubation.
The Luciferase Assay System from Promega was used to determine gene expression
following the manufacturer’s recommended protocol. The light units were normalized
against protein concentration in the cells’ extracts, which were measured using the
Coomassie Plus™ Protein Assay (Thermo Scientific). The transfection results were
expressed as Relative Light Units (RLU) per mg of cellular protein.
Assessment of Cytotoxicity (MTS Assay)
Cytotoxicity of polymers was determined by the Cell-Titer 96® Aqueous Cell Proliferation
Assay (Promega). A549 cells were grown as described in the transfection experiments. Cells
were treated with the samples for ~24 h. The media were then removed and replaced with a
mixture of 100µL fresh culture media and 20µL MTS reagent solution. The cells were
incubated for 3 h at 37°C in the 5% CO2 incubator. The absorbance of each well was then
measured at 490 nm using a microtiter plate reader (SpectraMax, M25, Molecular Devices
Corp., CA) to determine cell viability.
SYBR Green Assay of TAT and PEI Complexes
The degree of pDNA accessibility following complexation with TAT or PEI was assessed
by the double-stranded-DNA-binding reagent SYBR Green (Invitrogen). Briefly, 10 µL (0.1
mg/mL) of pDNA was mixed with 15 µL of TAT or PEI solution, then 15 µL deionized
water or metal solution was added. Complexes were allowed to form for 30 min at room
temperature prior to use. After incubation, 120 µL deionized water and 160 µL 10× SYBR
Green solutions were added. And then 80 µL of sample was added to three wells of a 96-
well cell culture plate. The fluorescence was measured using a fluorescence plate reader
(SpectraMax M5; Ex., 250 nm; Em, 520 nm).
TNBS Assay of TAT and PEI Complexes
The accessibility of free amine groups of TAT or PEI following complexation with pDNA
was measured using a colorimetric assay with 2,4,6-trinitro-benzenesulphonic acid (TNBS)
as an assay reagent (Pierce). Briefly, 10 µL of complex solution was added to 190 µL
deionized water and then 200 µL of 0.02 % TNBS solution in 0.1 M sodium bicarbonate
buffer (pH 8.5) was added. The solution was rapidly mixed. After incubation at 37°C for 2
h, 80 µL of sample was added to three wells of a 96-well cell culture plate. The absorption at
335 nm was determined using a plate reader.
Baoum et al. Page 5






















The Effect of Heparin on the Stability of TAT and PEI Complexes
The effect of heparin on the stability of complexes was evaluated by the means of the
change in fluorescence intensity obtained with the fluorescent probe SYBR Green. TAT and
PEI complexes were freshly prepared in absence and the presence of CaCl2 (0.3 M) as above
described. 120 µL of heparin solution was added to these various complexes to yield final
diverse heparin concentrations up to 50µg/µL, incubated for 30 min at room temperature and
then 160 µL 10× SYBR Green was added. In triplicate, 80 µL of each sample was added to
the well of 96-well plate and the fluorescence was measured as indicated in SYBR Green
assay.
Statistical Analysis
Statistical evaluation of comparing the significance of the difference in expression between
the means of two groups was performed using the t-test, a value of p <0.05 was accepted as
significant.
RESULTS
Formation of TAT-Ca/pDNA and PEI/pDNA Complexes
TAT and PEI complexes were prepared by mixing pDNA with each polycation at various
N/P ratios as described. In order to demonstrate complex formation, a gel electrophoresis
assay was performed using 1% agarose gel. Uncomplexed pDNA was used as a control. Gel
electrophoresis indicated that pDNA complexed with polycations could be retained in the
loading wells. Above a certain N/P ratio, no bands were observed during electrophoresis,
indicating that TAT and PEI completely complexed the pDNA. Under these conditions,
CaCl2 showed negligible ability to complex the plasmid DNA even at high concentration (1
M) (Fig. 1).
Morphological and Physical Characterization of TAT-Ca/pDNA and PEI/pDNA Complexes
The effect of calcium chloride concentration on the particle size and surface charge of TAT/
pDNA and PEI/pDNA complexes was investigated. Over a certain concentration range,
calcium addition to TAT/pDNA complexes induced a substantial decrease in the particle
size. In comparison, PEI/pDNA complexes showed an increase in particle size (Fig. 2A).
The added CaCl2 concentration range of 0.3–0.5 M (113–188 mM final CaCl2
concentration) produced small (50–100 nm) and stable TAT/pDNA complexes with
relatively narrow polydispersity (< 0.15). In general, the zeta potential of TAT and PEI
complexes increased significantly from 11 to 27 mV with increasing concentration of CaCl2
(Fig. 2B).
A transmission electron microscope (FEI field emission transmission electron microscope,
Tecnai G2 at 200 kV) equipped with an energy-dispersive analytical X-ray (EDAX) was
used to image the morphology of the TAT/pDNA and TAT-Ca/pDNA complexes and to
characterize elements in these complexes, respectively. TEM samples were prepared by
depositing a drop of the complex suspension on a copper carbon grid and allowing it to dry
in a dessicater overnight. Transmission electron micrographs of TAT/pDNA complexes
revealed an asymmetric morphology. The darker areas in TAT-Ca/pDNA seemed to suggest
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calcium trapped inside the particles (Fig. 3A and B). Samples were imaged using scanning
transmission electron microscopy and analyzed using EDAX spectroscopy to detect the
location of calcium. EDAX spectrum for two labeled areas in the scanning transmission
electron micrograph (on the particles and substrate) revealed significantly higher calcium
concentration in the particles compared to free calcium that would have dried on the
substrate (Fig. 4A, B and C).
The stability of TAT and PEI complexes was investigated as a function of time in the
absence and presence of 0.3 M CaCl2 and 10% FBS (Fig. 5A and B). TAT/pDNA
complexes including 0.3 M CaCl2 remained stable in the absence and presence of 10% FBS
over a period of 8 days. Conversely, PEI/pDNA complexes showed a marked increase in
size.
Cytotoxicity of TAT and PEI Complexes
Low cytotoxicity together with high transfection efficiency are extremely important
attributes for nonviral gene vectors. The cytotoxicity of free TAT, PEI, and CaCl2 was
studied by incubating A549 cells with up to 5 mg/mL of TAT or PEI and with up to 0.5 M
CaCl2 (Fig. 6A and B). TAT peptide revealed no evidence of cytotoxicity, and cells
maintained high viability. Branched PEI induced significant cytotoxicity (IC50 ~35µg/mL).
CaCl2 alone showed modest cytotoxicity (IC50 ~210 mM).
In Vitro Transfection Efficiency of TAT-Ca/pDNA and PEI/pDNA Complexes
The in vitro transfection efficiency of these complexes was studied using the human lung
carcinoma cell line A549. Luciferase gene expression was evaluated on day 1 of transfection
using the TAT or PEI polyplexes including different concentrations of CaCl2 during the
complex formation. TAT complexes showed a higher level of gene expression at 0.3 M
CaCl2 when compared to PEI, which had excellent transfection efficiency in the absence of
CaCl2 (Fig. 7). It was interesting that the optimized level of gene expression of TAT-Ca/
pDNA complexes was similar to the transfection efficiency of branched PEI and increased
over the first four days. Conversely, the gene expression of PEI/pDNA complexes showed a
marked decrease during the same time-frame. The gene expression was sustained for at least
10 days, and TAT-Ca/pDNA complexes appeared to be superior to PEI/DNA complexes at
day 8 and 10 (Fig. 8). Strikingly, no expression was observed for TAT/pDNA complexes
without CaCl2. In addition, PEI-Ca/pDNA complexes exhibited lower levels of gene
expression compared to PEI/pDNA complexes. It is important to note that the optimum gene
transfection for TAT-Ca/pDNA complexes occurred when 0.3 M of CaCl2 was added,
which yields a final CaCl2 concentration of 113 mM, well below the CaCl2 IC50 value of
210 mM.
The Effect of Serum on Transfection Efficiency and Particle Size
It has been previously reported that the presence of serum may have a significant influence
on the transfection efficiency of nonviral gene delivery vehicles (55–57). To determine the
effect of serum on gene expression, A549 cells were transfected with optimized TAT-Ca/
pDNA (0.3 M CaCl2) or PEI/pDNA complexes in the absence and presence of 10% FBS.
Results indicated that serum did not significantly inhibit the transfection efficiency mediated
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by TAT-Ca/pDNA complexes. In contrast, PEI complexes showed slightly decreased
transfection efficiency in the presence of 10% FBS (Fig. 9). The effect of serum on
transfection efficiency should be considered in light of the stability of the size of TAT and
PEI complexes which were investigated as a function of time. TAT/pDNA complexes
without CaCl2 exhibited some agglomeration behavior in the absence and presence of 10%
of FBS after 8 days (Fig. 5A and B). However, TAT-Ca/pDNA complexes showed good
stability in serum-free and supplemented culture media during the same time-frame. On the
other hand, PEI/pDNA complexes remained stable in the absence of serum and CaCl2 over a
period of 8 days and retained their size, whereas the particle size of PEI-Ca/pDNA showed a
marked decrease during the same time-frame in the presence of serum.
SYBR Green Assay
Dye displacement assays provide a simple, nondestructive, and high throughput method for
investigating the pDNA accessibility within complexes. Various concentrations of CaCl2
were examined to identify the effect on pDNA packaging. SYBR green, which binds
double-stranded DNA, was used for the assay (58). TAT/pDNA complexes showed weak
fluorescence intensity. The addition of different CaCl2 concentrations up to 0.3 M likely
condensed the TAT complexes, which resulted in lowering the accessibility of pDNA (Fig.
10A). The fluorescence intensity transitioned into a gradual increase with increasing
concentration of CaCl2. In contrast, PEI/pDNA complexes exhibited a negligible
fluorescence for all concentrations of CaCl2 except at 0 and 2 M CaCl2, where slight
fluorescence intensities were observed.
TNBS Assay
A TNBS assay was also used to determine the accessibility of the primary amine groups
within the TAT/pDNA or PEI/pDNA complexes. The TNBS assay revealed that the free
TAT had more primary amine groups than PEI, which decreased to negligible levels when
adding the designated volume of 0.3 M CaCl2 to them (Fig. 10B). Control studies indicated
that adding 62.5 mM CaCl2 decreased the absorption intensity of TNBS by less than 10%.
Increasing CaCl2 concentration did not affect the absorption intensity further. These results
supported the hypothesis that the efficiency of DNA compaction was increased by the
introduction of CaCl2. Therefore, calcium interaction with amines also facilitated the
observed stabilization and decrease in particle size for TAT/pDNA complexes. PEI
complexes including CaCl2 showed low binding of the dye as well, but this may result from
particle agglomeration or precipitation as suggested by the particle size studies.
Stability of Complexes Exposed to Heparin
The stability of TAT and PEI complexes when exposed to the biological polyanion heparin
was studied by determining changes in the SYBR Green-pDNA fluorescence. Exposing the
complexes to heparin yielded an increase in the fluorescence signal as the heparin
concentration increased (Fig. 11). TAT and PEI complexes including 0.3 M CaCl2 showed
release of the plasmid DNA from the complexes at lower heparin concentrations than
without calcium. These results indicated that calcium may control the delicate balance
between binding affinities within polycations and pDNA complexes.
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Improvement in the field of gene therapy is currently hindered by the lack of translatable
gene delivery vectors. Synthetic, nonviral, vehicles based on polycations are promising
vectors for gene delivery (59–64). The toxicity of these materials may be reduced or
eliminated by reducing polycation molecular weight. However, the levels of gene expression
mediated by low molecular weight polycations are typically low compared to higher
molecular weight polycations (e.g. 25 kDa PEI) (65,66). As a result, many researchers have
aimed to improve upon the deficiency of either system.
Among nonviral vehicles, cell-penetrating peptides (CPPs) have been used to deliver a
variety of therapeutics. For example, experimental anti-cancer cargo including small
molecules, proteins and nucleic acids, were delivered into cells in vitro using CPPs and have
been explored to treat preclinical tumor models in vivo (67,68). Complexes of plasmid DNA
with TAT peptides have been used in gene delivery either by covalent coupling of the
peptide to the vectors, or by simple mixing of the plasmid DNA with the TAT peptide to
form TAT/pDNA complexes via electrostatic interactions. However, the transfection
efficiency for these complexes was quite low in comparison to PEI.
In our studies, TAT/pDNA complexes alone also exhibited no gene expression. The size of
these complexes was quite large (~1,000 nm) for gene delivery. Therefore, calcium was
explored as a condensing agent to reduce the size of TAT/pDNA complexes and to improve
transfection efficiency. Calcium was found to form tight and compact complexes (~60 nm)
through “soft” crosslinks that could be competitively disrupted in order to increase
transfection efficiency. The precise balance between binding affinities within TAT/pDNA
polyplexes was adjusted by controlling CaCl2 concentration as a means to optimize
transfection efficiency. Previous studies have shown that both small and larges particles may
provide efficient levels of gene expression (69–72). However, the condensed size of TAT-
Ca/pDNA complexes in this study appeared to correlate with enhanced transfection
efficiency.
The ability of calcium to condense TAT/pDNA complexes occurred as a result of calcium
interactions with both amines (polycations) and phosphates (DNA). The binding affinity of
calcium to double-stranded DNA was observed as indicated by gel electrophoresis of the
TAT-Ca/pDNA complexes. A specific CaCl2 concentration range was necessary to achieve
small particles. Dye displacement studies provided some indication of the extent of
compaction of DNA when bound to TAT or PEI. Nearly complete exclusion of TNBS from
both TAT/pDNA and PEI/pDNA complexes was achieved when 0.3 M calcium was added
to the polyplexes, suggesting that the primary amine groups within these complexes were
blocked. Moreover, pDNA was mostly inaccessible to SYBR green when TAT/pDNA
complexes were formulated with up to 0.3 M CaCl2, suggesting that pDNA was also
extensively condensed within the complexes. The accessibility of pDNA increased at higher
concentrations of CaCl2 which demonstrated that calcium may also competitively inhibit the
amine/phosphate interaction.
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The stability of TAT and PEI complexes upon exposure to the polyanion heparin revealed
that complex dissociation depended on the inclusion of calcium as well. Heparin and
heparan sulfate have been previously reported to bind to PEI and release pDNA from
complexes (73,74). Complex stability is significant because sufficiently low affinity
between polycation and plasmid DNA may be desirable to facilitate the release of the DNA
after cellular uptake. The inclusion of calcium in the formulation of TAT and PEI complexes
facilitated the dissociation of these complexes by heparin. Therefore, the release of pDNA
from the complexes suggested that a critical concentration of calcium can condense the
complexes into small particles yet facilitate the release of DNA.
A successful gene delivery system should be able to deliver DNA to the cell without
negatively affecting the viability of the host cell. A cytotoxicity study in A549 human lung
carcinoma cells indicated that TAT peptide provided substantially higher cell viability than
PEI. Further studies will be necessary to determine if this gene vector is benign in primary
human cells.
CONCLUSION
Drug delivery strategies using CPPs such as TAT have been widely explored to improve the
intracellular delivery of a large number of cargo molecules. Electrostatic complexation of
pDNA using TAT has been less explored due to the relatively low levels of gene expression
observed when using such low molecular weight polycations as DNA condensing agents.
We have found that the binding affinity of calcium for TAT peptide and pDNA can be used
to effectively mediate the charge balance within these complexes. In this study, it was
shown that 0.3 M CaCl2 produced small and stable TAT/pDNA complexes via “soft”
crosslinks leading to gene expression levels higher than observed for control PEI gene
vectors in A549 lung epithelial cells. TAT-Ca/pDNA complexes were stable, maintaining
particle size in the absence and presence of 10% of FBS over a period of 8 days. Gene
expression of TAT-Ca/pDNA complexes was sustained for at least 10 days and tended to
increase over the first four days of the study. Conversely, gene expression levels for PEI/
pDNA complexes showed high initial gene expression that dropped to low levels after day 4.
Moreover, the transfection efficiency of TAT-Ca/pDNA complexes was not significantly
influenced by the presence of serum. The TAT peptide also showed negligible cytotoxicity
up to 5 mg/mL. In comparison, PEI was very cytotoxic (IC50 ~35µg/mL). Thus, these data
suggest that TAT-Ca complexes are a novel and effective vehicle offering some potential for
translatable gene delivery.
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Gel electrophoresis study of (a) CaCl2/pDNA complexes; 1=0.1 M, 2=0.2 M, 3=0.3 M,
4=0.4 M, 5=0.5M, 6=0.6M, 7=0.7 M, 8=0.8M, 9=0.9 M, 10=1.0 M, 11=3 M, 12=5 M and
13=7 M of CaCl2. (b) TAT/pDNA complexes. (c) TAT-Ca/pDNA N/P 25 complexes; 1=0
mM, 2=62.5 mM, 3=125 mM, 4=250 mM, 5=300 mM, 6=350 mM, 7=400 mM, 8=500 mM,
9=1 M and 10=2 M of CaCl2. (d) TAT/pDNA complexes with 0.3 M CaCl2. (e) Branched
PEI/pDNA complexes. (f) Linear PEI/pDNA complexes.
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The effect of CaCl2 concentration on (A) particle size and (B) charge of PEI/pDNA
complexes (N/P 5, N/P 10) and TAT-Ca/pDNA (N/P 25) complexes. Data are presented as
mean±SD (n=3).
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Transmission electron micrograph of (A) TAT/pDNA and (B) TAT-Ca/pDNA.
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(A) Scanning transmission electron micrograph and EDAX spectrum of TAT-Ca/pDNA.
The characterized areas (B) on particles and (C) on substrate are indicated in the scanning
transmission electron micrograph. EDAX spectra showed the elemental composition of
particles and substrate (Cu peaks result from the copper grid).
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The stability of TAT-Ca/pDNA and PEI/pDNA complexes over time in (A) the absence and
(B) presence of 10%FBS. Results are presented as mean±SD (n=3).
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Cytotoxicity profiles of (A) PEI, TAT and (B) CaCl2. Viability is expressed as a function of
polymer concentration. Results are presented as mean±SD (n=3).
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The transfection efficiency of TAT-Ca/pDNA and PEI/pDNA polyplexes with different
concentration of CaCl2. Results are presented as mean±SD (n=3).
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The transfection efficiency of TAT-Ca/pDNA and PEI/pDNA polyplexes with and without
0.3 M CaCl2. Results are presented as mean±SD (n=3). * p<0.001.
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Transfection efficiency of TAT-Ca/pDNA and PEI/pDNA complexes in A549 cells in the
absence or presence of 10% FBS. Results are presented as mean±SD (n=3).
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(A) Effect of CaCl2 concentration on the TAT/pDNA and PEI/pDNA complexes by using
the SYBR Green assay to assess DNA accessibility and (B) condensation of TAT and PEI
complexes assessed using the TNBS assay as a probe for amine accessibility. Results are
presented as mean±SD (n=3).
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Unpackaging of TAT and PEI complexes by heparin displacement of DNA. Results are
presented as mean±SD (n=3).
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